Page last updated: 2024-11-05

aminacrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminacrine is an acridine derivative with a long history of research and therapeutic exploration. Its synthesis involves a multi-step process, often starting with the condensation of a substituted aniline with an aldehyde. Aminacrine exhibits several pharmacological effects, including inhibition of acetylcholinesterase, an enzyme involved in the breakdown of acetylcholine, a neurotransmitter crucial for muscle function and memory. This property has led to its investigation as a potential treatment for Alzheimer's disease, although its use in this context has been limited due to concerns about toxicity. Aminacrine has also shown activity against a variety of pathogens, including bacteria and viruses. Its mechanism of action in these cases often involves disruption of microbial membranes or interference with key metabolic processes. Despite its potential, aminacrine has not been widely adopted as a therapeutic agent due to its limited efficacy, concerns about safety, and the emergence of alternative treatments. Nevertheless, research into aminacrine continues, with ongoing efforts to explore its potential as a lead compound for the development of new and more effective therapies.'

Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7019
CHEMBL ID43184
CHEBI ID74789
SCHEMBL ID14999
MeSH IDM0000909
PubMed CID11352
CHEMBL ID146525
SCHEMBL ID167452
MeSH IDM0000909

Synonyms (158)

Synonym
BIDD:GT0816
BRD-K00535541-001-02-2
acridin-9-yl-amine
nsc-28747
nsc28747
DIVK1C_006957
SPECTRUM_001108
10-amino-5-azaanthracene
izoacridina
acridine, 9-amino-
9aa ,
nsc-13000
9-aminoacridine
9-acridinamine
90-45-9
wln: t c666 bnj iz
aminoacridine
monacrin
aminacrine
aminacrin
nsc13000
SPECTRUM5_001498
acridin-9-amine ,
9-aa
nsc 13000
aminoacridina
aminoacridine [inn:ban]
ccris 748
9-aminoacridin
brn 0141171
aminoacridinum
9-aminoakridin [czech]
ai3-51012
einecs 201-995-6
CU-01000012501-2
8AD ,
7AD ,
smr000420251
MLS000780068 ,
acridin-9-ylamine
NCGC00094857-02
NCGC00094857-01
KBIO3_001654
KBIO2_004156
KBIO2_001588
KBIO1_001901
KBIOSS_001588
KBIOGR_001020
KBIO2_006724
SPECPLUS_000861
SPECTRUM4_000580
SPECTRUM2_001112
SPECTRUM3_000617
SPBIO_001244
SPECTRUM1500810
BSPBIO_002154
NCGC00094857-03
aminopt
mykocert
STK387428
HMS2092K22
CHEMBL43184
chebi:74789 ,
xjgfwwjlmvzsig-uhfffaoysa-
inchi=1/c13h10n2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8h,(h2,14,15)
HMS1921I16
AKOS000120447
CS-003/03975023
nsc-757794
pharmakon1600-01500810
nsc757794
9-aminoakridin
65944-23-2
S4303
CCG-39037
unii-78oy3z0p7z
78oy3z0p7z ,
FT-0621612
4BDS
9-acridinylamine
SCHEMBL14999
aminoacridine [who-dd]
aminacrine [vandf]
aminacrine [mi]
aminoacridine [inn]
CS-4915
9-amino-acridine
pentafluoropropionaldehydemethylhemiacetal
iminoacridan
bdbm72700
cid_2723598
acridin-9-ylamine;hydrate;hydrochloride
9-acridinamine;hydrate;hydrochloride
HY-B1422
mycosert (salt/mix)
acramine yellow (salt/mix)
quench (salt/mix)
AB00052180_09
AB00052180_10
DTXSID2024456
9-aminoacridine, 97%
mfcd00037839
9-aminoacridine, matrix substance for maldi-ms, >=99.5% (hplc)
sr-01000760844
SR-01000760844-2
SBI-0051612.P002
HMS3715H04
SW219793-1
DB11561
BCP25849
Q513937
SY039786
9-amino-acridin
AS-17405
BRD-K00535541-311-04-1
AC2194
EN300-17076
aminoacrid
9-aminoacridine free base
9-aminoacridine (purified by sublimation)
1-aminoakridin
unii-lb79bvp4v6
lb79bvp4v6 ,
5-22-11-00004 (beilstein handbook reference)
1-aminoakridin [czech]
ccris 2105
4-aminoacridine (european)
nsc 170666
brn 0141124
nsc-170666
1-aminoacridine
nsc170666
wln: t c666 bnj gz
578-06-3
acridine, 1-amino-
1-acridinamine
acridinamine
MLS000521341 ,
smr000131749
CHEMBL146525
acridin-1-ylamine
acridin-1-amine
NCGC00245933-01
AKOS006279834
27254-80-4
HMS2232G08
HMS3373O03
AB00453386-17
AB00453386-14
SCHEMBL167452
LOMMDWBTANPFEJ-UHFFFAOYSA-N
aminoacridin
bdbm48247
cid_11352
OPERA_ID_786
DTXSID40870623
1-amino-acridin
FT-0775279

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic and mutagenic effects of the alkylating agents methylnitrosourea (MNU) and methylnitronitrosoguanidine (MNNG) and of the frameshift mutagen, ICR-191 were compared among 3 human diploid lymphoblast lines, MIT-2, WI-L2 and GM 130."( Comparison of toxicity and mutagenicity of methylnitrosourea, methylnitronitrosoguanidine and ICR-191 among human lymphoblast lines.
Andon, BM; Slapikoff, SA; Thilly, WG, 1980
)
0.26
" No evidence was found for more adverse events that occurred in different drug groups than placebo group."( Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Bai, Y; Chen, W; He, J; He, M; Hou, D; Jiang, Q; Li, X; Liu, X; Luo, B; Ma, Q; Ma, X; Qin, Y; Shang, L; Sun, L; Tang, M; Wang, T; Wang, X; Wu, L; Xiao, S; Xie, H; Zhao, Z, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
"To investigate how the physicochemical properties and pharmacokinetics of SM-10888 are altered by metabolic reactions, physicochemical and pharmacokinetic parameters of its phase I and phase II metabolites were determined."( Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
Iba, K; Mine, T; Nakatsuka, I; Yabuki, M; Yoshitake, A,
)
0.13
" In addition, the absorption, distribution, and metabolism properties are characterized by determining metabolic stability, MDCK accumulation, Pgp efflux transport, plasma protein binding, and brain distribution in mouse pharmacokinetic studies."( 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.
Bedi, J; Benoit, AR; Ferguson, DM; Gallardo, JL; Giri, R; Morizio, KM; Ohlfest, JR; Olin, MR; Remmel, RP; Teitelbaum, AM, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Although the intercalating ability of these ring systems lead to high sensitivity for detection of reduced metabolites in vitro by flow cytometry, poor bioavailability is an unwanted consequence of intercalation."( Nitroaryl compounds as potential fluorescent probes for hypoxia. I. Chemical criteria and constraints.
Clarke, ED; Hodgkiss, RJ; Middleton, RW; Parrick, J; Stratford, MR; Wardman, P, 1984
)
0.27
" Their conjugation with biomolecules such as peptides and proteins may modulate their activity, bioavailability and applicability."( A role of the 9-aminoacridines and their conjugates in a life science.
Hlavácek, J; Sebestík, J; Stibor, I, 2007
)
0.34
" The bioavailability was calculated to be 83."( 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.
Bedi, J; Benoit, AR; Ferguson, DM; Gallardo, JL; Giri, R; Morizio, KM; Ohlfest, JR; Olin, MR; Remmel, RP; Teitelbaum, AM, 2012
)
0.38
"Taken overall, the results suggest compounds in this series may offer new strategies for the design of chemotherapeutics for treating brain cancers with high oral bioavailability and improved efficacy."( 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.
Bedi, J; Benoit, AR; Ferguson, DM; Gallardo, JL; Giri, R; Morizio, KM; Ohlfest, JR; Olin, MR; Remmel, RP; Teitelbaum, AM, 2012
)
0.38
" They need to be adopted to generate a new branch of acridine conjugates, enhancing their bioavailability for the examination in biological systems."( Efficient and Short Method for Conjugation of 1-Nitro-9-Aminoacridine to Important Peptidyl Fragments by a Solid Support Synthesis.
Lahutta, M, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Mutational dose-response studies with X-rays, ethyl methanesulfonate (EMS), and ICR-191 were conducted in 4 of these revertant cell lines."( Heritable alterations at the adenine phosphoribosyltransferase (APRT) locus in human lymphoblastoid cell lines.
Amundson, SA; Fortunato, JE; Liber, HL, 1992
)
0.28
" The UV dose-response curve of mus-26 showed a characteristic plateau in the range of 100-200 J/m2."( Epistasis, photoreactivation and mutagen sensitivity of DNA repair mutants upr-1 and mus-26 in Neurospora crassa.
Inoue, H; Ishii, C, 1989
)
0.28
" The dam+/pMQ148, dam-2/pMQ148 and dam-1/pMQ148 strains showed identical dose-response curves for both 9AA and ICR191."( A mutation in the DNA adenine methylase gene (dam) of Salmonella typhimurium decreases susceptibility to 9-aminoacridine-induced frameshift mutagenesis.
Hall, RM; Podger, DM; Ritchie, L, 1988
)
0.27
" A comparison of the Ca2+ dose-response curves for release of the various granule constituents indicated that elastase was being secreted along with other contents of the azurophil granules."( The kinetics of secretion from permeabilized human neutrophils: release of elastase and correlations with other granule constituents and right angle light scatter.
Sklar, LA; Smolen, JE; Stoehr, SJ; Traynor, AE, 1987
)
0.27
"3 to 150 mg/sq m/day; (b) toxicity in the form of stomatitis, vomiting, and phlebitis occurred at dosage levels of 125 to 150 mg/sq m/day; and (c) oncolytic effects were observed in 13 of 24 patients."( Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Dahl, GV; Evans, WE; Pratt, CB; Rivera, G; Yee, GC, 1980
)
0.26
" Luminescence of the A16 strain (luxE mutant) increased significantly after a few hours of such a treatment with various mutagenic agents, revealing a dose-response correlation."( A modified Vibrio harveyi mutagenicity assay based on bioluminescence induction.
Podgórska, B; Wegrzyn, G, 2006
)
0.33
" harveyi mutagenicity assay is rapid, sensitive and reveals a dose-response correlation for various mutagens."( A modified Vibrio harveyi mutagenicity assay based on bioluminescence induction.
Podgórska, B; Wegrzyn, G, 2006
)
0.33
"The efficacy results indicate low micromolar ED(50) values against glioma cells and a significant increase in the survival of glioma-bearing mice dosed with (2) (p < 0."( 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.
Bedi, J; Benoit, AR; Ferguson, DM; Gallardo, JL; Giri, R; Morizio, KM; Ohlfest, JR; Olin, MR; Remmel, RP; Teitelbaum, AM, 2012
)
0.38
" It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg."( Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
fluorescent dyenull
MALDI matrix materialA compound used to form the matrix for MALDI (matrix-assisted laser desorption/ionization) mass spectrometry. MALDI matrix materials are crystalline compounds with a fairly low molecular weight, so as to allow facile vaporization, have strong absorption at UV or IR wavelengths (to rapidly and efficiently absorb laser irradiation), generally contain polar groups (enabling them to be used in aqueous solutions) and are frequently acidic (so assisting ionisation of the compound being studied, which is contained within the matrix material).
acid-base indicatorAn acid or base which exhibits a colour change on neutralization by the basic or acidic titrant at or near the equivalence point of a titration.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoacridinesAcridines which are substituted in any position by one or more amino groups or substituted amino groups. Note that the term 'aminoacridine' is the International Prorietary Name (INN) for 9-aminoacridine.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (52)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
TDP1 proteinHomo sapiens (human)Potency3.46350.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
67.9K proteinVaccinia virusPotency28.18380.00018.4406100.0000AID720579; AID720580
alpha-galactosidaseHomo sapiens (human)Potency40.07494.466818.391635.4813AID1467; AID2107
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency28.18380.016525.307841.3999AID602332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency15.84890.001815.663839.8107AID894
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2546
DNA polymerase kappa isoform 1Homo sapiens (human)Potency31.62280.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
caspase-1 isoform alpha precursorHomo sapiens (human)Potency15.84890.000311.448431.6228AID900
Caspase-7Homo sapiens (human)Potency12.58933.981118.585631.6228AID889
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.18380.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency25.11895.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency14.81120.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency6.91040.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency17.78280.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency3.54810.28189.721235.4813AID2326
67.9K proteinVaccinia virusPotency28.18380.00018.4406100.0000AID720580
glucocerebrosidaseHomo sapiens (human)Potency15.84890.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency28.18384.466818.391635.4813AID1467; AID2107
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency28.18380.016525.307841.3999AID602332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency29.33010.036619.637650.1187AID1466; AID2112; AID2242
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.81840.01262.451825.0177AID485313
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency4.61090.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency26.83340.794321.275750.1187AID624246; AID651804
importin subunit beta-1 isoform 1Homo sapiens (human)Potency7.07955.804836.130665.1308AID540253
DNA polymerase betaHomo sapiens (human)Potency8.91250.022421.010289.1251AID485314
polypyrimidine tract-binding protein 1 isoform aHomo sapiens (human)Potency21.03273.981115.308231.6228AID2730; AID2731; AID2733; AID2734
ras-related protein Rab-9AHomo sapiens (human)Potency2.81840.00022.621531.4954AID485297
eyes absent homolog 2 isoform aHomo sapiens (human)Potency794.32801.199814.641950.1187AID488837
snurportin-1Homo sapiens (human)Potency7.07955.804836.130665.1308AID540253
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency15.84890.010323.856763.0957AID2662
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency7.07955.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.06270.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency7.07950.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency28.18383.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency28.18383.548118.039535.4813AID1466
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.99531.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)0.44500.00271.62879.9000AID1566052; AID1566061
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)26.00000.00002.37899.7700AID1888748
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)112.00000.00001.89149.5700AID1888749
Trypanothione reductaseTrypanosoma cruziKi38.00000.07605.15297.6000AID214657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
matrix metalloproteinase 1, partialHomo sapiens (human)EC50 (µMol)21.90001.060010.759427.6000AID618
short transient receptor potential channel 6 isoform 1Mus musculus (house mouse)EC50 (µMol)50.12000.020020.518970.7900AID2696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CAAX prenyl protease 2 isoform 2Homo sapiens (human)AC505.07002.080018.126987.2100AID588849
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC504.75000.814019.311978.9500AID651657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID54962Percentage of the sum of the amplitudes evaluated in the kinetic experiment; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID54264Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1129462Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species.
AID357846Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
AID214657The competitive inhibitory activity against trypanothione reductase was evaluated from Lineweaver Burk plots1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships.
AID54974DNA dissociation constant was determined from calf thymus1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID1566055Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1150100Ionization constant, pKa of the compound by UV spectrophotometric analysis1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.
AID54811Ratio T2/T1 of DNA dissociation constant from calf thymus1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID234990Time constant describing the dissociation profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID234985Time constant describing the dissociation profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1769487Aqueous solubility of the compound
AID152666Compound administered intraperitoneally was evaluated for optimal dose (OD) given per day after inoculation of 10e 6 P388 leukemia cells for highest nontoxic dose1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID54979DNA dissociation constant from calf thymus; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID1888750Selectivity index, ratio IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID234991Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 3 min; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID54970DNA dissociation constant from calf thymus1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID54830Percentage of the sum of the amplitudes evaluated in the kinetic experiment1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID54256Inhibitory concentration against ethidium bromide binding to DNA1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.
AID1145952Inhibition of Escherichia coli DNA-primed RNA polymerase activity using [8-14C]ATP at 200 ug/ml by scintillation counting1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID54263DNA-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID228718Difference between log K of (AT) and log K of (GC) DNA binding1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID234984Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 1 min; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID54265Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM; 9.4 x 10 e-3 epcilonfor equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID234989Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 2 min; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1145958Inhibition of Escherichia coli DNA-primed RNA polymerase activity using [8-14C]ATP at 25 ug/ml by scintillation counting1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID227507Fraction of the observed equilibrium absorbance change accounted in the kinetic analysis; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID539396Displacement of ethidium bromide from calf thymus DNA by fluorometric assay2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Design and synthesis of threading intercalators to target DNA.
AID153997The % increase in lifespan of treated animals over that of control group of animals injected with tumor alone1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.
AID55131Logarithm of association constant for binding to DNA by ethidium displacement1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID209937Minimal bacteriostatic concentration against streptococcus pyogenes under conditions of pH 7.3, 37 degree C; 1 in 1600001982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Fourth Smissman Award Address. The long search for valid structure-action relationships in drugs.
AID1566056Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID152935Cytotoxic effect in human peripheral blood monocyte cells(PBMC)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.
AID1566054Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID1566052Inhibition of recombinant human NQO2 expressed in Escherichia coli using DCPIP as substrate by spectrophotometry2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID1145954Inhibition of Escherichia coli DNA-primed RNA polymerase activity using [8-14C]ATP at 100 ug/ml by scintillation counting1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID1320098Genotoxicity in Salmonella typhimurium TA1537 assessed as number of revertant colonies per plate at 80 ug/plate after 20 mins in absence of S9 fraction by Ames test (Rvb = 9 No_unit)2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID357845Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID1457287Genotoxicity in Salmonella typhimurium TA1537 assessed as number of revertants per plate at 75 ug/plate in absence of rat liver S9 fraction by Ames test (Rvb = 19 +/- 9 No_unit)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID152669Highest nontoxic optimal dose administered intraperitoneally after inoculation of P388 leukemia cells1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.
AID225780Association constant for binding to poly(dA-dT) DNA in 0.01 SHE buffer, measured by ethidium displacement method for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID153868Percentage increase in life span treated animals over those of controls injected with P388 leukemia cells1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID54266Micelle-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID344297Cytotoxicity against mouse ScN2a cells assessed as maximal tolerant concentration2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Antiprion activity of functionalized 9-aminoacridines related to quinacrine.
AID1566057Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID1566061Inhibition of NQO2 in human SKOV3 cells assessed as reduction in cell viability in presence of 1 uM CB1954 and EPR incubated for 24 hrs measured after 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID539395Cytotoxicity against human HL60 cells by MTS assay2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Design and synthesis of threading intercalators to target DNA.
AID225923Association constant for binding to poly(dG-dC) DNA in 0.01 SHE buffer, measured by ethidium displacement method for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID81416Inhibitory effect against HIV-1 in human peripheral blood monocyte cells(PBMC); Not evaluated for HIV-1 inhibition due to high cytotoxicity.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.
AID98315Evaluated for concentration which when added to cultures of L1210 leukemia cells for a period of 70 hr reduces cell numbers of 50% of control cultures1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID19849Maximum reversion frequency1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
On the significance of clusters in the graphical display of structure-activity data.
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID539397Growth inhibition of human HL60 cells2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Design and synthesis of threading intercalators to target DNA.
AID26537log K value (Logarithm of DNA-affinity association constant)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
On the significance of clusters in the graphical display of structure-activity data.
AID26756DNA binding dissociation constant as KD1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID227384Fraction of the observed equilibrium absorbance change accounted in the kinetic analysis1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID20509Lipophilicity (Rm)1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.
AID1129465Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxidative damage at less than cytotoxic EC50 after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species.
AID1566058Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID1888749Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID96818In vitro inhibitory dose that reduces L1210 cell line by 50% when added for a period of 70h1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.
AID54813Ratio T3/T2 of DNA dissociation constant from calf thymus; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID1145950Inhibition of Escherichia coli DNA-primed RNA polymerase activity using [8-14C]ATP at 400 ug/ml by scintillation counting1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID1145956Inhibition of Escherichia coli DNA-primed RNA polymerase activity using [8-14C]ATP at 50 ug/ml by scintillation counting1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID1769488Binding affinity to salmon DNA assessed as DNA intercalation measured after 30 mins by UV based spectroscopic method
AID54817Ratio T4/T3 of DNA dissociation constant from calf thymus; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID54977DNA dissociation constant from calf thymus; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents.
AID1566059Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2013The Biochemical journal, Aug-01, Volume: 453, Issue:3
Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745846Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID209936Minimal bacteriostatic concentration against streptococcus pyogenes under conditions of pH 7.3, 37 degree C; 1 in 100001982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Fourth Smissman Award Address. The long search for valid structure-action relationships in drugs.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (519)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990219 (42.20)18.7374
1990's104 (20.04)18.2507
2000's83 (15.99)29.6817
2010's94 (18.11)24.3611
2020's19 (3.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.07 (24.57)
Research Supply Index6.30 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index53.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.56%)5.53%
Trials0 (0.00%)5.53%
Reviews4 (0.74%)6.00%
Reviews0 (0.00%)6.00%
Case Studies2 (0.37%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other530 (98.33%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]